

## **June 2012 DUR BOARD PDL MEETING MINUTES**

**Date:** June 27, 2012

**Members Present:** Wilkinson, Anglim, Brown, Burton, Caldwell, Cobb, Fitzgerald, Harrison, Maxwell.

**Others Present:** Dan Peterson, Dave Campana (Medicaid), Kathy Novak (Magellan), Woodmansey and Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

Lisa called the meeting to order.

**Public Comment Period:** No one offered public comment at this time.

The May DUR Board meeting minutes were reviewed and approved.

### **Department Update:**

Dan Peterson informed the Board that Amy Holodnick has resigned as the Pharmacy Program Officer. The Department is seeking a replacement.

### **PDL Review:**

The Department reviewed the following classes as **NEW** information is known to exist. The Board made the following recommendations to the Department:

- ADHD/CNS STIMULANTS – Trial of 2 preferred agents required; Grandfathered category
  - Must have 1 long acting agent and 1 short acting agent; May add others
- HEMATOPOIETIC AGENTS- Grandfathered category
  - Therapeutic alternatives
- ANTICOAGULANTS
  - Must have 1 LMWH; Must have warfarin; May add others. Remove warfarin trial requirement for Pradaxa and add criteria for appropriate use.
- PLATELET INHIBITORS- Grandfather current dipyridamole patients only
  - Must have ASA, and Aggrenox; May add dipyridamole; Class effect for clopidogrel, Effient and Brilinta-Must have 1.
- LONG ACTING NARCOTICS- Grandfathered category
  - Must have one long- acting morphine or long- acting oxycodone; May add others
- SKELETAL MUSCLE RELAXANTS
  - Must have baclofen; Other agents are therapeutic alternatives.
- GLAUCOMA-ALPHA 2 ADRENERGICS -Must have at least one of brimonidine, Alphagan or Alphagan P; May add iopidine.
- GLAUCOMA-BETA BLOCKERS - Class effect.
- GLAUCOMA- CARBONIC ANHYDRASE INHIBITORS – (full review) Must have one single agent; May add others.
- GLAUCOMA-PROSTAGLANDINS – Class effect. Must have diagnosis of glaucoma (criteria currently in place)
- SEDATIVE HYPNOTICS-
  - Therapeutic alternatives; must have 1 benzodiazepine and 1 BZ-1 selective agent; May add ramelteon
- ANTIHYPERTENSIVES, SYMPATHOLYTICS - New Category. Grandfathered .

- Therapeutic alternatives; Must have a clonidine product; Must have a guanfacine product; May add others.
- ANTIHYPERURICEMICS – New Category. Not Grandfathered
  - Must have allopurinol; Must have colchicine with criteria for appropriate use; May add probenecid; May add Uloric with currently existing criteria
- ANDROGENIC AGENTS, TOPICAL- New Category - Not Grandfathered
  - Class effect
- ATYPICAL ANTIPSYCHOTICS-
  - Must have Abilify (aripiprazole), risperidone, quetiapine, and ziprasidone. May add others.

The Department proposed no changes to the Formulary Committee's previous clinical recommendations.

(The following classes were not reviewed because no **NEW** information was submitted)

The Board made the following recommendations to the Department:

- ANTIDEPRESSANTS, OTHER – Grandfathered category
  - Must have bupropion XL, trazodone, mirtazapine, venlafaxine ER, and Cymbalta (duloxetine); May add others.
- ANTIDEPRESSANTS, SSRI - Grandfathered category
  - Class effect
- ANTIMIGRAINE AGENTS – Grandfathered category
  - Must have one nasal spray, must have one injectable and must have one short acting agent; May add a long acting agent. Short acting agents have a class effect.
- NASAL CALCITONINS –
  - Class effect
- BISPHOSPHONATES AND BONE RESORPTION OTHERS: Class effect for bisphosphonates, others are therapeutic alternatives.
- GROWTH HORMONES – Grandfathered Category; Therapeutic alternatives
- OPHTHALMIC ALLERGIC CONJUNCTIVITIS – Class effect
- OPHTHALMIC ANTIBIOTICS – Class effect
- OTIC ANTIBIOTICS & COMBOS – Class effect.
- PHOSPHATE BINDERS – Class effect.
- TOPICAL ANALGESICS/ANESTHETICS – Not Grandfathered
  - Therapeutic alternatives for all agents; PA criteria for diclofenac products.

There were no green classes for this meeting

The next meeting will be a DUR Board meeting on Wednesday September 26, 2012 at the MPQHF Building at 3404 Cooney Drive at 1:00.

The meeting was adjourned at 4:00.